MX2007006343A - Forma farmaceutica multiparticulada que comprende ingredientes activos de acido nucleico mucoadhesivamente formulado y un proceso para producir la forma farmaceutica. - Google Patents
Forma farmaceutica multiparticulada que comprende ingredientes activos de acido nucleico mucoadhesivamente formulado y un proceso para producir la forma farmaceutica.Info
- Publication number
- MX2007006343A MX2007006343A MX2007006343A MX2007006343A MX2007006343A MX 2007006343 A MX2007006343 A MX 2007006343A MX 2007006343 A MX2007006343 A MX 2007006343A MX 2007006343 A MX2007006343 A MX 2007006343A MX 2007006343 A MX2007006343 A MX 2007006343A
- Authority
- MX
- Mexico
- Prior art keywords
- administration
- nucleic acid
- producing
- active ingredients
- multiparticulate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invencion trata de una forma farmaceutica multiparticulada oral que comprende granulos que tienen un tamano que varia entre 50 y 2500 ??m, que esencialmente estan compuestos de una capa de a) una matriz interior que comprende nanoparticulas que comprenden un ingrediente activo de acido nucleico, y se incorpora en una matriz de un polimero que tiene efecto mucoadhesivo y b) un revestimiento pelicular exterior que comprende un esencia un polimero o copolimero anionico que opcionalmente se puede formular con excipientes farmaceuticamente acostumbrados, en especial plastificantes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004059792A DE102004059792A1 (de) | 2004-12-10 | 2004-12-10 | Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Nukleinsäure-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform |
PCT/EP2005/011864 WO2006061069A1 (de) | 2004-12-10 | 2005-11-05 | Multipartikuläre arzneiform, enthaltend mucoadhaesiv formulierte nukleinsäure-wirkstoffe, sowie ein verfahren zur herstellung der arzneiform |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2007006343A true MX2007006343A (es) | 2007-07-04 |
Family
ID=35709359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2007006343A MX2007006343A (es) | 2004-12-10 | 2005-11-05 | Forma farmaceutica multiparticulada que comprende ingredientes activos de acido nucleico mucoadhesivamente formulado y un proceso para producir la forma farmaceutica. |
Country Status (17)
Country | Link |
---|---|
US (1) | US8568778B2 (es) |
EP (1) | EP1824457B1 (es) |
JP (1) | JP5578764B2 (es) |
KR (1) | KR101319773B1 (es) |
CN (1) | CN101060835B (es) |
BR (1) | BRPI0515815B8 (es) |
CA (1) | CA2586597C (es) |
DE (1) | DE102004059792A1 (es) |
ES (1) | ES2569354T3 (es) |
HK (1) | HK1110205A1 (es) |
HU (1) | HUE028793T2 (es) |
IL (1) | IL183753A (es) |
MX (1) | MX2007006343A (es) |
PL (1) | PL1824457T3 (es) |
SI (1) | SI1824457T1 (es) |
TW (1) | TW200635617A (es) |
WO (1) | WO2006061069A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8048413B2 (en) | 2006-05-17 | 2011-11-01 | Helene Huguet | Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules |
WO2008002568A2 (en) * | 2006-06-26 | 2008-01-03 | Mutual Pharmaceutical Company, Inc. | Active agent formulations, methods of making, and methods of use |
US20110038939A1 (en) * | 2007-07-16 | 2011-02-17 | Northeastern University | Therapeutic stable nanoparticles |
DE102008048729A1 (de) * | 2008-09-24 | 2010-03-25 | Add Technologies Ltd Advanced Drug Delivery | Multipartikuläre Tabletten und Verfahren zur deren Herstellung |
US20130064896A1 (en) * | 2009-12-29 | 2013-03-14 | Laman Lynn Alani | Gastroretentive Solid Oral Dosage Forms with Swellable Hydrophilic Polymer |
KR101708086B1 (ko) | 2010-02-25 | 2017-02-17 | 에보니크 룀 게엠베하 | 제약 또는 기능식품 제제 |
CN102250878B (zh) * | 2011-06-03 | 2013-01-23 | 吉林大学 | 一种基于固相介质表面电荷的反转提取dna的方法 |
US9107851B2 (en) * | 2012-10-15 | 2015-08-18 | New Jersey Institute Of Technology | Solventless mixing process for coating pharmaceutical ingredients |
JP6912876B2 (ja) * | 2016-10-06 | 2021-08-04 | 三洋化成工業株式会社 | アクリル系医薬固形製剤用添加剤 |
CN110603057A (zh) * | 2017-03-17 | 2019-12-20 | 俄亥俄州创新基金会 | 用于递送化学预防剂的纳米颗粒 |
SG11202005949UA (en) | 2018-05-24 | 2020-07-29 | Celanese Eva Performance Polymers Corp | Implantable device for sustained release of a macromolecular drug compound |
CN111971026A (zh) | 2018-05-24 | 2020-11-20 | 塞拉尼斯伊娃高性能聚合物公司 | 用于持续释放大分子药物化合物的可植入器件 |
DE102020002360A1 (de) * | 2020-04-18 | 2021-10-21 | Friedrich-Schiller-Universität Jena | Nanopartikel enthaltend Komplexe aus Nukleinsäuren und kationischen Copolymeren, Verfahren zu deren Herstellung und deren Verwendung zum Gentransfer in Zellen |
WO2023249087A1 (ja) * | 2022-06-24 | 2023-12-28 | 三生医薬株式会社 | 医薬組成物およびその製造方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW209174B (es) | 1991-04-19 | 1993-07-11 | Takeda Pharm Industry Co Ltd | |
EP0859857B1 (en) * | 1995-10-25 | 2005-05-04 | OctoPlus B.V. | Cationic polyacrylates and poly(alkyl)acrylates or the corresponding acrylamides for use in synthetic transfection systems |
GB9700624D0 (en) | 1997-01-14 | 1997-03-05 | Danbiosyst Uk | Drug delivery composition |
US6730735B2 (en) * | 1997-07-03 | 2004-05-04 | West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited | Conjugate of polyethylene glycol and chitosan |
EP1203590B1 (en) * | 1999-08-09 | 2007-07-04 | Dainippon Sumitomo Pharma Co., Ltd. | Solid preparations containing chitosan powder and process for producing the same |
US7803392B2 (en) * | 2000-12-27 | 2010-09-28 | University Of Kentucky Research Foundation | pH-Sensitive mucoadhesive film-forming gels and wax-film composites suitable for topical and mucosal delivery of molecules |
US20030017195A1 (en) * | 2001-07-20 | 2003-01-23 | Samir Mitragotri | Method for oral drug delivery |
US7670627B2 (en) * | 2002-12-09 | 2010-03-02 | Salvona Ip Llc | pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients |
DE10332160A1 (de) | 2003-07-15 | 2005-02-03 | Röhm GmbH & Co. KG | Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform |
DE10353196A1 (de) | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix |
DE10353186A1 (de) | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz |
US20040224019A1 (en) * | 2004-03-03 | 2004-11-11 | Adi Shefer | Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs |
DE102004036437A1 (de) | 2004-07-27 | 2006-03-23 | Röhm GmbH & Co. KG | Multipartikuläre Arzneiform für wenig lösliche Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform |
DE102006035549A1 (de) | 2006-07-27 | 2008-01-31 | Evonik Röhm Gmbh | Arzneiform mit mindestens zweischichtiger Trennschicht |
-
2004
- 2004-12-10 DE DE102004059792A patent/DE102004059792A1/de not_active Withdrawn
-
2005
- 2005-11-05 HU HUE05807707A patent/HUE028793T2/hu unknown
- 2005-11-05 KR KR1020077012902A patent/KR101319773B1/ko active IP Right Grant
- 2005-11-05 PL PL05807707T patent/PL1824457T3/pl unknown
- 2005-11-05 WO PCT/EP2005/011864 patent/WO2006061069A1/de active Application Filing
- 2005-11-05 BR BRPI0515815A patent/BRPI0515815B8/pt active IP Right Grant
- 2005-11-05 CN CN200580037293XA patent/CN101060835B/zh active Active
- 2005-11-05 EP EP05807707.4A patent/EP1824457B1/de active Active
- 2005-11-05 ES ES05807707.4T patent/ES2569354T3/es active Active
- 2005-11-05 JP JP2007544750A patent/JP5578764B2/ja active Active
- 2005-11-05 SI SI200532058A patent/SI1824457T1/sl unknown
- 2005-11-05 CA CA2586597A patent/CA2586597C/en active Active
- 2005-11-05 MX MX2007006343A patent/MX2007006343A/es unknown
- 2005-11-05 US US11/721,399 patent/US8568778B2/en active Active
- 2005-11-16 TW TW094140339A patent/TW200635617A/zh unknown
-
2007
- 2007-06-07 IL IL183753A patent/IL183753A/en active IP Right Grant
-
2008
- 2008-01-21 HK HK08100739.8A patent/HK1110205A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP1824457B1 (de) | 2016-02-17 |
KR20070085894A (ko) | 2007-08-27 |
CN101060835A (zh) | 2007-10-24 |
CA2586597C (en) | 2013-09-10 |
JP2008522989A (ja) | 2008-07-03 |
US8568778B2 (en) | 2013-10-29 |
BRPI0515815A (pt) | 2008-08-05 |
IL183753A (en) | 2016-12-29 |
ES2569354T3 (es) | 2016-05-10 |
CN101060835B (zh) | 2013-01-02 |
BRPI0515815B1 (pt) | 2019-02-05 |
SI1824457T1 (sl) | 2016-06-30 |
PL1824457T3 (pl) | 2016-07-29 |
DE102004059792A1 (de) | 2006-06-14 |
IL183753A0 (en) | 2007-09-20 |
HUE028793T2 (hu) | 2017-01-30 |
TW200635617A (en) | 2006-10-16 |
HK1110205A1 (en) | 2008-07-11 |
CA2586597A1 (en) | 2006-06-15 |
KR101319773B1 (ko) | 2013-10-17 |
BRPI0515815B8 (pt) | 2021-05-25 |
WO2006061069A1 (de) | 2006-06-15 |
JP5578764B2 (ja) | 2014-08-27 |
US20090280183A1 (en) | 2009-11-12 |
EP1824457A1 (de) | 2007-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2007006343A (es) | Forma farmaceutica multiparticulada que comprende ingredientes activos de acido nucleico mucoadhesivamente formulado y un proceso para producir la forma farmaceutica. | |
DE502004005154D1 (de) | Multipartikuläre arzneiform, enthaltend mucoadhaesiv formulierte peptid- oder protein-wirkstoffe, sowie ein verfahren zur herstellung der arzneiform | |
CY1105908T1 (el) | Στοματικως αποσαθρουμενα δισκια που πepιλαμβανουν βενζιμιδαζολιο | |
HUP0401714A2 (hu) | Propiverin vagy gyógyászatilag elfogadható sóinak nyújtott hatóanyag-eladású, orális adagolási formái | |
WO2006039499A3 (en) | Method for improving the biovailability of orally delivered therapeutics | |
WO2011084593A3 (en) | Abuse-resistant formulations | |
WO2008008617A3 (en) | Methods of making compositions comprising films | |
WO2004062577A3 (en) | Two or more enteric materials to regulate drug release | |
JP2009536147A5 (es) | ||
WO2004056337A3 (en) | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats | |
WO2005039499A3 (en) | Rapidly disintegrating film | |
NZ603579A (en) | Controlled release formulations | |
TW200719915A (en) | Flavoring of drug-containing chewing gums | |
WO2007150075A3 (en) | Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone | |
BRPI0513904A (pt) | forma farmacêutica de multipartìcula para substáncias ativas de baixa solubilidade e um processo para preparar a forma farmacêutica | |
AU2003231126A1 (en) | Chewable soft capsule | |
WO2008052033A3 (en) | Ibuprofen composition | |
JP2010510260A5 (es) | ||
JP2007238598A5 (es) | ||
WO2008142572A3 (en) | Controlled release tablet formulation containing magnesium aluminometasilicate | |
BG108516A (en) | Pharmaceutical formulation | |
GB0204772D0 (en) | Pharmaceutical dosage forms | |
WO2005107702A3 (en) | Sustained release, mucoadhesive vaginal pharmaceutical compositions | |
WO2007123883A3 (en) | Oral dosage formulations and methods of preparing the same | |
WO2003063840A3 (en) | Transmucosal delivery of proton pump inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC | Change of company name or juridical status |